Trials / Available
AvailableNCT05356052
Expanded Access for Patients With Pulmonary Hypertension Associated With Pulmonary Fibrosis
Expanded Access: Pulsed, Inhaled Nitric Oxide (iNO) for the Treatment of Patients With Serious Disease or Conditions Associated With Pulmonary Hypertension
- Status
- Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Bellerophon · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
An expanded access program that provides INOpulse treatment to patients with serious disease or conditions associated with pulmonary hypertension associated with pulmonary fibrosis who are not able to participate in the Sponsor's ongoing Phase 3 REBUILD clinical.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| COMBINATION_PRODUCT | INOpulse | Patients will be treated by means of an INOpulse device using an INOpulse nasal cannula |
Timeline
- First posted
- 2022-05-02
- Last updated
- 2023-02-21
Source: ClinicalTrials.gov record NCT05356052. Inclusion in this directory is not an endorsement.